Determining Predictors of Early Response to Exenatide in Patients with Type 2...
Our study identified that baseline HbA1c acted as the sole predictor of exenatide response and that response may be determined after 3 months of exenatide administration (Journal of Diabetes Research)
View ArticleThe association of the treatment with glucagon-like peptide-1 receptor...
Treatment with exenatide, with or without concomitant insulin was associated with reduced macrovascular risks compared to insulin; although inherent potential bias in epidemiological studies should be...
View ArticleBydureon 2 mg powder and solvent for prolonged-release suspension for...
Each pre-filled pen contains 2 mg of exenatide. After reconstitution, each pen delivers a dose of 2 mg in 0.65 ml (EMC)
View ArticleEffects of exenatide on postprandial vascular endothelial dysfunction in type...
Exenatide inhibited postprandial vascular endothelial dysfunction after the meal loading test, suggesting that exenatide has a multiphasic anti-atherogenic action involving not only glucose but also...
View ArticleAstraZeneca presents safety and efficacy data for ExQW at 51st Annual Meeting...
AstraZeneca today announced new analyses of exenatide once weekly (ExQW) demonstrating a favorable gastrointestinal (GI) tolerability profile, including less frequent upper and lower GI adverse events...
View ArticleGLP-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine...
These findings suggest that potential adverse pancreatic effects of GLP-1 receptor agonists are not mediated by changes in exocrine pancreatic secretion (Diabetes, Obesity and Metabolism)
View ArticleExenatide Treatment Causes Suppression of Serum Ghrelin Levels following...
These results suggest that the effect of exenatide on weight loss may be related with the suppression of serum ghrelin levels, which is an orexigenic peptide (Journal of Diabetes Research)
View ArticleExenatide Improves Beta-cell Function up to 3 Years of Treatment in Patients...
Compared to insulin glargine, exenatide improved parameters of beta-cell function, especially insulin secretion at 8 mmol/L glucose and beta-cell glucose sensitivity, which was sustained during the...
View ArticleExenatide once weekly plus dapagliflozin once daily versus exenatide or...
Co-initiation of exenatide and dapagliflozin improved various glycaemic measures and cardiovascular risk factors in patients with type 2 diabetes inadequately controlled by metformin monotherapy. The...
View ArticleGlucagon-like peptide-1 receptor agonists compared with basal insulins for...
Although weight reduction is seen with all GLP-1RA’s, only the once weekly agents, exenatide LAR and dulaglutide, demonstrate significant HbA1c reductions when compared to basal insulins (Diabetes,...
View ArticleExenatide once weekly plus dapagliflozin once daily versus exenatide or...
Co-initiation of exenatide and dapagliflozin improved various glycaemic measures and cardiovascular risk factors in patients with type 2 diabetes inadequately controlled by metformin monotherapy. The...
View ArticleEfficacy and safety of autoinjected exenatide once-weekly suspension versus...
This study demonstrated that exenatide QWS-AI reduced HbA1c more than sitagliptin or placebo and was well tolerated (Diabetes, Obesity and Metabolism)
View ArticleThree-year efficacy and safety of exenatide once weekly: A pooled analysis of...
Exenatide QW improved glycemic outcomes and was well tolerated in patients with T2D for up to 156 weeks (Diabetes and Its Complications)
View ArticleA Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide...
ExeOW is a well-tolerated and convenient option for long-term treatment of T2D allowing significant and persistent glycemic control with moderate weight loss and low risk of hypoglycemia unless...
View ArticleEffects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
Among patients with type 2 diabetes with or without previous cardiovascular disease, the incidence of major adverse cardiovascular events did not differ significantly between patients who received...
View ArticleGlucose Control and Weight Change Associated with Treatment with Exenatide...
In this real-world data analysis, exenatide QW and exenatide BID were associated with similar glycemic control and greater weight reduction compared with basal insulin (Diabetes Therapy)
View ArticleThe effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor...
This review indicates that GLP-1 has no short-term effect on REE but may decrease DIT. The GLP-1RA exenatide and liraglutide had a neutral effect on REE, although it was not possible to rule out an...
View ArticleSafety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily...
Among patients with type 2 diabetes uncontrolled with metformin, exenatide QW plus dapagliflozin provided sustained improvements in glycemia, weight, and SBP over 52 weeks, with no unexpected safety...
View ArticleEfficacy and safety of meal-time administration of short-acting exenatide for...
Short-acting exenatide does not seem to have a future as a standard add-on treatment to insulin therapy in type 1 diabetes (The Lancet Diabetes & Endocrinology)
View Article
